Strong Financial Performance

Abbott Laboratories announced a robust first quarter for 2025, with revenues climbing to $10.4 billion, marking a 4% increase from the previous year. The company's net earnings soared to $1.3 billion, reflecting an 8.2% year-on-year growth, and diluted earnings per share (EPS) rose by 8.6% to $0.76.

Leadership's Perspective

"Abbott's diversified business model has once again proven its strength, delivering top-tier sales and EPS growth. This strategic diversification and execution enable us to navigate through uncertainties and sustain growth," stated CEO Robert Ford. The company has confidently reaffirmed its 2025 guidance, projecting organic sales growth between 7.5% and 8.5%, an adjusted operating margin of 23.5% to 24.0% of sales, and adjusted diluted EPS ranging from $5.05 to $5.25.